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1,25-Dihydroxyvitamin D3 Selectively Modulates Tolerogenic
Properties in Myeloid but Not Plasmacytoid Dendritic Cells1
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Marisa Vulcano,† Silvano Sozzani,† and Luciano Adorini2*
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) is an immunomodulatory agent inducing dendritic cells (DCs) to become tolerogenic. To
further understand its mechanisms of action, we have examined the effects of 1,25(OH)2D3 on tolerogenic properties of blood
myeloid (M-DCs) and plasmacytoid (P-DCs) human DC subsets. Exposure of M-DCs to 1,25(OH)2D3 up-regulated production of
CCL22, a chemokine attracting regulatory T cells, whereas production of CCL17, the other CCR4 ligand, was reduced.
1,25(OH)2D3 also decreased IL-12p75 production by M-DCs, as expected, and inhibited CCR7 expression. 1,25(OH)2D3 treatment
markedly increased CD4 suppressor T cell activity while decreasing the capacity of M-DCs to induce Th1 cell development.
Surprisingly, 1,25(OH)2D3 did not exert any discernible effect on tolerogenic properties of P-DCs, and even their high production
of IFN- was not modulated. In particular, the intrinsically high capacity of P-DCs to induce CD4 suppressor T cells was
unaffected by 1,25(OH)2D3. Both DC subsets expressed similar levels of the vitamin D receptor, and its ligation by 1,25(OH)2D3
similarly activated the primary response gene cyp24. Interestingly, 1,25(OH)2D3 inhibited NF-B p65 phosphorylation and nuclear
translocation in M-DCs but not P-DCs, suggesting a mechanism for the inability of 1,25(OH)2D3 to modulate tolerogenic properties
in P-DCs. The Journal of Immunology, 2007, 178: 145–153.
T he activated form of vitamin D, 1,25-dihydroxyvitaminD3 (1,25(OH)2D3),3 is a secosteroid hormone that has, inaddition to its central function in calcium and bone me-
tabolism, important effects on the growth and differentiation of
many cell types and pronounced immunoregulatory properties (1–
4). The biological effects of 1,25(OH)2D3 are mediated by the
vitamin D receptor (VDR), a member of the superfamily of nuclear
hormone receptors functioning as a agonist-activated transcription
factor that binds to specific DNA sequence elements, vitamin D
responsive elements, in vitamin D responsive genes and ultimately
influences their rate of RNA polymerase II-mediated transcrip-
tion (5).
APCs, and notably dendritic cells (DCs), express the VDR and
are key targets of VDR agonists, both in vitro and in vivo. A
number of studies has clearly demonstrated that 1,25(OH)2D3 and
its analogs markedly modulate DC phenotype and function (6–11).
These studies, performed either on monocyte-derived DCs from
human peripheral blood or on bone marrow-derived mouse DCs,
have consistently shown that in vitro treatment of DCs with
1,25(OH)2D3 and its analogs leads to down-regulated expression
of the costimulatory molecules CD40, CD80, CD86, and to de-
creased IL-12 and enhanced IL-10 production, resulting in de-
creased T cell activation. The block of maturation, coupled with
abrogation of IL-12 and strongly enhanced production of IL-10,
highlight the important functional effects of 1,25(OH)2D3 and its
analogs on DCs and are, at least in part, responsible for the induc-
tion of DCs with tolerogenic properties (12).
DCs are heterogeneous in terms of origin, morphology, pheno-
type, and function. Two distinct DC subsets, defined as myeloid
DCs (M-DCs) and plasmacytoid DCs (P-DCs), have been identi-
fied in human and mouse blood (13–15). Human and mouse DCs
of lymphoid and myeloid origin express a different repertoire of
pattern recognition receptors and are characterized by a different
cytokine production profile. P-DCs produce large amounts of type
I IFNs in response to viruses and other pathogens, whereas M-DCs
are the main IL-12 producers (16). Likewise, P-DCs and M-DCs
produce a different pattern of chemokines (17) and exhibit a dif-
ferent migratory response upon exposure to a variety of ligands
(18). The different properties of DC subsets highlight their com-
plementary roles in the induction and regulation of innate and
adaptive immune responses. M-DCs are the most efficient APCs
directly able to prime naive T cells and can become, under differ-
ent conditions, immunogenic or tolerogenic (19). P-DCs, under
steady-state conditions, appear to play a key role in maintaining
peripheral immune tolerance, and may be considered naturally oc-
curring tolerogenic DCs (16).
Although the immunomodulatory effects of 1,25(OH)2D3 on
DCs are well established, the capacity of this hormone to modulate
DC subsets has not yet been addressed. In the present study, we
have analyzed the immunomodulatory effects of 1,25(OH)2D3 on
human blood M-DCs and P-DCs. The results demonstrate a dif-
ferential capacity of 1,25(OH)2D3 to modulate cytokine and che-
mokine production in DC subsets, showing marked effects in M-
DCs and negligible ones in P-DCs. Also inhibition of Th1
development and enhancement of CD4 suppressor T cell activity
are selectively induced by 1,25(OH)2D3 in M-DCs but not P-DCs.
This different capacity of DC subsets to respond to 1,25(OH)2D3 is
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not due to a diverse VDR expression or to VDR-dependent signal
transduction, but is associated with differential effects of this
hormone on NF-B p65 phosphorylation and nuclear translo-
cation in DC subsets. The selective modulation of tolerogenic
properties in DC subsets has important implications for under-
standing the immunoregulatory role of 1,25(OH)2D3.
Materials and Methods
Peripheral blood DC purification and culture
PBMCs were isolated from buffy coats by Ficoll gradient (Pharmacia Bio-
tech), and peripheral blood M-DCs and P-DCs were magnetically sorted
with blood DC Ag (BDCA)-1 and BDCA-4 cell isolation kits (Miltenyi
Biotec), respectively, as described (20), to a purity of 95–98% in both
cases. Blood M-DCs and P-DCs (2  104 cells/well) were cultured as
described (18) in RPMI 1640 culture medium supplemented with 10% FCS
(HyClone), 2 mM L-glutamine, 50 g/ml gentamicin, 1 mM sodium pyru-
vate, and 1% nonessential amino acids (complete medium) containing 10
ng/ml recombinant human GM-CSF (BD Pharmingen) or 20 ng/ml IL-3
(BD Pharmingen), respectively. DC subset cells were stimulated with 1
g/ml LPS (Escherichia coli O111:B4; Sigma-Aldrich), 6 g/ml CpG oli-
gonucleotide 2006 (MWG Biotec), CD40L (CD154)-transfected J558L
cells at a ratio of 4:1, or PMA (100 ng/ml) plus ionomycin (1 g/ml), both
from Sigma-Aldrich. Crystalline 1,25(OH)2D3 was a gift of M. Uskokovic
(BioXell), dexamethasone was purchased from Sigma-Aldrich, and recom-
binant human IL-10 from BD Pharmingen.
CD4 T cell purification and culture
CD4 T cells were purified from PBMC by negative selection with CD4
T cell isolation kit (Miltenyi Biotec), and CD4CD45RA T cells were
subsequently negative selected with CD4CD45RO beads (Miltenyi Bio-
tec). CD4 T cell were cocultured with allogenic ex vivo purified blood
M-DC or P-DC in complete medium with or without 10 nM 1,25(OH)2D3.
After 6 days of culture, CD4 T cells were stained for the detection of
intracellular IFN-, IL-4, and IL-2 as previously described (21).
Assay for suppressive activity
Peripheral blood naive CD4 T cells, purified as previously described from
donor C, were cultured in the presence of purified DC subsets from donor
D (ratio 1:10) with or without 10 nM 1,25(OH)2D3. At 7–10 days after
primary stimulation, cells were restimulated under the same conditions.
After two rounds of restimulation, CD4 T cells were tested for suppres-
sive activity. The read-out system was composed of CD4CD25 cells
from donor A PBMCs cultured in the presence of 1:10 LPS-matured mono-
cyte-derived DCs from donor B. To evaluate the induction of regulatory T
cells, graded amounts of CD4 T cells from donor C, generated by three
rounds of restimulation with allogeneic DC subsets from donor D, were
added to the MLR read-out culture system. The suppression assay was
performed in the presence of 1 g/ml anti-human CD3 mAb. After 72 h of
culture, IFN- production in culture supernatants was quantified by two-
site ELISA.
Chemokine and cytokine quantification
Concentrations of CCL17/TARC (R&D Systems), CCL22/MDC (R&D
Systems), IL-12p75 (BD Pharmingen), IFN- (Bender MedSystem) in DC
subset culture supernatants were evaluated by sandwich ELISA according
to the manufacturer’s instructions. IFN- concentration was determined
using paired mAb, as described previously (6). Detection limits were
5–15 pg/ml.
Flow cytometric analysis
Flow cytometric analysis was performed as previously described (17), in
the presence of 200 g/ml mouse IgG, using the mAbs anti-CD1c
(BDCA-1) FITC or PE, anti-BDCA-2 FITC, or PE (Miltenyi Biotec), anti-
HLA-DR (BD Pharmingen), and anti-CCR7 PE (BD Pharmingen). Anal-
ysis of NF-B p65 phosphorylation was performed using the
K10-895.12.50 PE mAb recognizing the phosphorylated S529 in the trans-
activation domain of NF-B p65 (BD Biosciences), according to the man-
ufacturer’s protocol. Cells were analyzed with a LSR flow cytometer (BD
Biosciences) using CellQuest software.
Real-time quantitative RT-PCR
RNA was extracted using TRIzol (Invitrogen Life Technologies) according
to the manufacturer’s instruction, followed by a cleanup with the RNeasy
kit (Qiagen). Reverse transcription was performed, and real-time quanti-
tative RT-PCR of total cDNA using specific primers was conducted using
an ABI PRISM 7000 Sequence Detection System (Applied Biosystems)
and TaqMan chemistry. The primers used are commercially available from
Applied Biosystems as assays-on-demand. Relative quantification of target
cDNA was determined by arbitrarily setting the control value to 1 and
changes in cDNA content of a sample were expressed as a multiple thereof.
Differences in cDNA input were corrected by normalizing to -actin or
GAPDH signals. To exclude amplification of genomic DNA, RNA samples
were treated with DNase (Sigma-Aldrich).
NF-B nuclear translocation
Cells placed on poly-L-lysine-coated glass slides were permeabilized with
0.1% Triton X-100 for 4 min at 4°C and stained with rabbit anti-NF-B
p65 Ab (Santa Cruz Biotechnology), followed by polyclonal anti-rabbit
FITC (Sigma-Aldrich). After washing, cells were stained with 2.5 g/ml
propidium iodide. Negative controls were performed by incubation with
appropriate isotype-matched primary Abs. The slides were then washed
again and mounted with 90% glycerol/PBS. Slides were analyzed with an
MRC-1024 confocal microscope (Bio-Rad). Images were acquired and
processed with Laser Sharp 3.2 software (Bio-Rad).
Results
1,25(OH)2D3 differentially modulates CCR4 ligand production
in M-DCs without affecting it in P-DCs
We have previously shown that production of the homeostatic che-
mokines CCL17 and CCL22 is strictly compartmentalized in hu-
man DC subsets, and is a prerogative of M-DCs (17). Data in Fig.
1 confirm the selective capacity of M-DCs but not P-DCs to con-
stitutively produce CCL17 and CCL22. In addition, they clearly
show an opposite effect of 1,25(OH)2D3 on the production of these
CCR4 ligands by M-DCs. CCL17 production is inhibited dose-
dependently by 1,25(OH)2D3 in culture supernatants of unstimu-
lated M-DCs after both 24 and 48 h of culture, whereas a marked
up-regulation of CCL22 production is observed in the same culture
supernatants. Conversely, neither CCL22 nor CCL17 production
was induced in P-DCs by 1,25(OH)2D3.
FIGURE 1. 1,25(OH)2D3 modulates constitutive production of CCR4
ligands in M-DCs but not in P-DCs. Magnetically purified blood M-DCs
and P-DCs (2  104 cells/well) were cultured in GM-CSF or IL-3, respec-
tively, in the presence of the indicated concentrations of 1,25(OH)2D3.
Secreted chemokines (ng/ml) were detected 24 h (Œ) and 48 h later (F) by
two-site ELISA. The data are from one representative experiment of five
performed.
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Next, the effect of 1,25(OH)2D3 on CCR4 ligand production by DC
subsets unstimulated or stimulated via CD40 ligation was compared
(Fig. 2). CD40 ligation up-regulated CCL17 production in M-DCs,
but failed to induce it in P-DCs (Fig. 2, see graphs), as previously
reported (17). 1,25(OH)2D3 inhibited constitutive and induced
CCL17 production by M-DCs equally well, with negligible effects on
its production by P-DCs (Fig. 2). Two other anti-inflammatory agents
targeting DCs, the glucocorticoid dexamethasone and IL-10, were
also tested. Opposite to 1,25(OH)2D3, dexamethasone markedly
up-regulated CCL17 production by M-DCs, whereas this pro-
duction was inhibited by IL-10 similarly to 1,25(OH)2D3. A
strong dose-dependent up-regulation of CCL17 was also in-
duced by dexamethasone in unstimulated and CD40L-stimu-
lated P-DCs, whereas no effect was induced by IL-10 (Fig. 2).
CCL22 production was up-regulated by CD40 ligation both in
M-DCs and P-DCs, as expected (17), and was further enhanced in
unstimulated but not stimulated M-DCs by 1,25(OH)2D3, whereas
a profound inhibition was induced by dexamethasone and IL-10 in
both unstimulated and stimulated M-DCs. In CD40L-stimulated
P-DCs, CCL22 production was again not substantially modulated
by 1,25(OH)2D3, but was decreased markedly by dexamethasone
and only slightly by IL-10.
1,25(OH)2D3 inhibits the Th1 cell-inducing capacity of
M-DCs but not P-DCs
1,25(OH)2D3 selectively affects DC subsets also in their capacity to
direct T cell development. Results in Fig. 3A show that both M-DC
and P-DC induce naive alloreactive CD4 T cells to differentiate
mainly into Th1 cells, as defined by intracytoplasmic staining for
IFN- and IL-4. M-DCs compared with P-DCs activate a larger pro-
portion of CD4 T cells characterized by production of both IFN-
and IL-2. Incubation with 1,25(OH)2D3 inhibits the Th1-inducing
capacity of M-DCs, as indicated by the selective inhibition of IFN-
-producing CD4 T cells, with a modest effect on IL-2-producing
CD4 T cells (Fig. 3A). Conversely, no effect on the Th1-inducing
capacity of P-DCs is exerted by 1,25(OH)2D3 (Fig. 3A). No observ-
able skewing to the Th2 phenotype was induced by 1,25(OH)2D3
treatment in cultures containing either M-DCs or P-DCs. To analyze
mechanisms potentially accounting for these differential effects, we
have determined the capacity of 1,25(OH)2D3 to modulate IL-12p75
and IFN- signature Th1-inducing cytokines selectively produced by
M-DCs and P-DCs, respectively (16). 1,25(OH)2D3 reduces IL-12p75
production by CD40L-stimulated M-DCs, whereas IFN- production
by P-DC is not affected, thus suggesting an explanation for the selec-
tivity of this agent in the inhibition of Th1 cell development (Fig. 3B).
In contrast to 1,25(OH)2D3, other DC-targeting immunomodulatory
agents, as dexamethasone and IL-10, inhibit constitutive and CD40L-
induced IFN- production by P-DCs (Fig. 3C).
1,25(OH)2D3 enhances the capacity of M-DCs but not
P-DCs to induce CD4 suppressor T cell activity
To evaluate the capacity of 1,25(OH)2D3 to modulate tolerogenic
properties of DC subsets, purified M-DCs and P-DCs were cultured
with allogenic naive CD4 cells for three rounds of restimulation in
the presence or absence of 1,25(OH)2D3. The marked IFN- produc-
tion of CD4CD25 cells (5853 pg/ml) is completely inhibited by
addition of blood CD4CD25 cells (Fig. 4A). M-DCs give rise to
CD4 cells with suppressive activity, which at a 1:1 cell ratio reduces
FIGURE 2. 1,25(OH)2D3, dexamethasone, and IL-10 modulate basal and CD40L-induced CCL17 and CCL22 production by M-DCs and P-DCs.
Magnetically purified M-DCs and P-DCs (2  104 cells/well) were cultured in GM-CSF or IL-3, respectively, with or without CD40L-transfected J558
cells (CD40L). The indicated concentrations of 1,25(OH)2D3, dexamethasone, or IL-10 were added at culture initiation. Mean and SE of secreted
chemokines (ng/ml) detected by two-site ELISA from 7 to 10 experiments are indicated. Data are representative of absolute values of chemokine production
after 48 h of culture in basal conditions and following CD40 ligation. The effects of immunomodulatory agents tested are expressed as a percentage of the
chemokine production in unstimulated control cultures.
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IFN- production by 60% from 5853 to 2418 pg/ml. This suppres-
sive activity is greatly enhanced by addition of 1,25(OH)2D3, leading
to near abrogation of IFN- production at 1:1 suppressor to target cell
ratio (Fig. 4B). P-DCs also induce CD4 cells with suppressive ac-
tivity, which appears to be slightly more potent compared with M-
DCs, inducing 84% suppression at 1:1 cell ratio, but in this case no
effect of 1,25(OH)2D3 can be observed (Fig. 4C).
1,25(OH)2D3 modulates MHC class II, Ig-like transcript (ILT)3,
and costimulatory molecule expression selectively in M-DCs
The selective capacity of 1,25(OH)2D3 to modulate cytokine and
chemokine production in M-DCs but not P-DCs, prompted us to
examine whether surface molecules crucial for DC activity were
differentially affected in DC subsets. To this end, we analyzed the
FIGURE 3. 1,25(OH)2D3 inhibits
the Th1 cell-inducing capacity of M-
DCs but not P-DCs. Magnetically pu-
rified blood DC subsets were cocul-
tured with allogeneic blood naive
CD4 cells for 7 days with or without
10 nM 1,25(OH)2D3. A, Percentage of
positive cells evaluated by cytofluo-
rimetry following intracellular stain-
ing for IFN-, IL-2, and IL-4. A rep-
resentative experiment of three
performed is shown. B, IL-12p75 and
IFN- production by magnetically
purified blood DC subsets cultured in
GM-CSF or IL-3, respectively. After
48 h of culture, DC subsets were stim-
ulated with CD40L-transfected J558
cells (CD40L) for additional 24 h
with or without 10 nM 1,25(OH)2D3.
Secreted IL-12p75 and IFN- (ng/ml)
were detected by two-site ELISA.
C, 1,25(OH)2D3, unlike dexametha-
sone or IL-10, fails to inhibit IFN-
production by P-DCs. Magnetically
purified M-DCs and P-DCs (2  104
cells/well) were cultured for 24 h in
GM-CSF or IL-3, respectively, with
medium alone or containing CD40L-
transfected J558 cells (CD40L). The in-
dicated concentrations of 1,25(OH)2D3,
dexamethasone, or IL-10 were added at
culture initiation. Mean and SE of se-
creted IFN- detected by two-site
ELISA from three independent experi-
ments are indicated.
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effects of 1,25(OH)2D3 on MHC class II and CD40 molecules, key
players in CD4 T cell responses, and expression of ILT3, an
inhibitory receptor expressed by tolerogenic DCs (11, 22). Incu-
bation with 1,25(OH)2D3 inhibited basal levels of MHC class II
and CD40 molecule expression in M-DCs but not P-DCs (Fig. 5A).
ILT3 expression was selectively up-regulated in M-DCs, while
it remained unaffected in P-DCs, following treatment with
1,25(OH)2D3 (Fig. 5A). In addition, no modulation of CD80 and
CD86 expression was induced by 1,25(OH)2D3 in P-DCs unstimu-
lated or stimulated with CD40L-transfected cells. In contrast, a
marked inhibition of CD80 and CD86 expression was induced by
1,25(OH)2D3 in M-DCs, either unstimulated or stimulated with
CD40L-transfected cells (Fig. 5B). CD40 ligation enhanced expres-
sion of costimulatory molecules in both DC subsets, up-regulating
FIGURE 4. 1,25(OH)2D3 enhances the capacity of
M-DCs but not P-DCs to induce CD4 suppressor T cell
activity. The read-out system to test for suppressive ac-
tivity was composed of CD4CD25 cells from donor
A PBMCs cultured with 1:10 DC subset cells from do-
nor B in the presence of 1 g/ml anti-human CD3 mAb.
To evaluate the induction of T cells with suppressive
activity, CD4 T cells from donor C were generated by
three rounds of restimulation with allogeneic DC sub-
sets from donor D cultured with or without 10 nM
1,25(OH)2D3. IFN- production was quantified in cul-
ture supernatants by two-site ELISA. A, IFN- produc-
tion by CD4CD25 cells (5  104/well) cultured alone
or with the indicated number of purified blood
CD4CD25 T cells. B, Suppressive activity of CD4
cells induced by allogenic M-DCs cultured with (cir-
cles) or without (triangles) 10 nM 1,25(OH)2D3. C, Sup-
pressive activity of CD4 cells induced by allogenic
P-DCs cultured with (circles) or without (triangles) 10
nM 1,25(OH)2D3.
FIGURE 5. 1,25(OH)2D3 modu-
lates MHC class II, ILT3, and co-
stimulatory molecule expression se-
lectively in M-DCs. Magnetically
purified blood M-DCs and P-DCs
(2  104 cells/well) were cultured in
GM-CSF or IL-3, respectively. A,
Surface expression of HLA-DR,
CD40, and ILT3 in unstimulated DC
subpopulations from a representative
donor cultured for 48 h in medium
alone or containing the indicated con-
centrations of 1,25(OH)2D3. B, Sur-
face expression of CD80 and CD86 in
DC subsets unstimulated or stimu-
lated with CD40L-transfected J558
cells (CD40L) cultured for 48 h in
medium alone or containing the indi-
cated concentrations of 1,25(OH)2D3.
Mean data from two individual donors
are shown. The geometric mean fluo-
rescence intensity (MFI) data represent
the percentage variation compared
with the marker expression in M-
DCs (E) or P-DCs (F) cultured
without 1,25(OH)2D3.
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CD80 mean fluorescence intensity from 438 to 1647 in M-DCs and
from 673 to 2981 in P-DCs, whereas CD86 mean fluorescence inten-
sity increased from 1352 to 6051 in M-DCs and from 426 to 3922
in P-DCs.
Gene modulation induced by 1,25(OH)2D3 in
M-DCs and P-DCs
Given the apparent lack of P-DC responsiveness to 1,25(OH)2D3,
we investigated VDR expression and response to 1,25(OH)2D3 in
DC subsets. A comparably high VDR expression was observed in
ex vivo purified M-DCs and P-DCs (Fig. 6), which was similar to
VDR expression detected in immature monocyte-derived DC and
monocytes (data not shown). VDR signal transduction was also
comparable in both DC subsets, as shown (Fig. 6) by the marked
up-regulation of cyp24, a primary VDR response gene encoding
the 24-hydroxylase enzyme catalyzing 1,25(OH)2D3 metabolism,
which is rapidly induced following exposure to 1,25(OH)2D3 (5).
Thus, both M-DCs and P-DCs express similar VDR levels, and
respond equally well to VDR ligation by up-regulating primary
response genes.
1,25(OH)2D3 inhibits NF-B phosphorylation and nuclear
translocation in M-DCs but not P-DCs
The transcription factor NF-B regulates in DCs expression of
genes encoding several cytokines and chemokines. NF-B family
proteins, c-Rel, RelA (p65), RelB, NF-B1 (p50), and NF-B2
(p52) are present in the cytoplasm in an inactive form as a result
of their association with the inhibitory proteins IB, IB, and
FIGURE 6. Gene modulation induced by 1,25(OH)2D3 in M-DCs and P-DCs. M-DCs and P-DCs express similar levels of VDR and up-regulate equally
well primary VDR response genes following stimulation with 1,25(OH)2D3. Magnetically purified blood M-DCs and P-DCs (2  10
4 cells/well) were
cultured with or without 10 nM 1,25(OH)2D3. After 2 h, RNA was extracted and expression of VDR and cyp24 transcripts evaluated by real-time RT-PCR.
Data are representative of arbitrary units normalized to GAPDH signals and are from one representative experiment of five conducted.
FIGURE 7. 1,25(OH)2D3 inhibits NF-B p65 phosphorylation and traps it into the cytoplasm in M-DCs but not P-DCs. Magnetically purified M-DCs
and P-DCs were cultured in GM-CSF or IL-3, respectively, with medium alone or containing 100 nM 1,25(OH)2D3 or 100 nM dexamethasone (Dex). After
an 18-h culture, M-DCs and P-DCs were incubated with medium only (unstimulated), or containing 100 ng/ml PMA plus 1 g/ml ionomycin (A and B),
1 g/ml LPS (C), or 6 g/ml CpG 2006 (D), respectively, for 45 min or as indicated. NF-B p65 phosphorylation was determined by cytofluorimetry. A,
The percentage of cells positive for phosphorylated S529 in the transactivation domain of NF-B p65, relative to controls, for 60 min after stimulation.
B, The geometric mean fluorescence intensity (MFI) of P-DCs positive for phosphorylated NF-B p65 at the indicated times after PMA-ionomycin
stimulation. Histogram analysis of positive cells is shown (right) 15 min after stimulation. C and D, Cells were fixed and stained with anti-NF-B p65 mAb
and propidium iodide (PI). Individual and merged stainings are shown. Original magnifications is 63.
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IB, and must be phosphorylated and translated to the nucleus to
become activated (23). To test whether 1,25(OH)2D3 could reduce
phosphorylation of NF-B p65, untreated and 1,25(OH)2D3-
treated M-DCs and P-DCs were stimulated with PMA with iono-
mycin, a nonspecific stimulus activating both subsets, and stained
with a mAb recognizing the phosphorylated S529 in the transac-
tivation domain of NF-B p65. Results in Fig. 7A show that phos-
phorylation of NF-B p65, detected by cytofluorimetry, was re-
duced by 1,25(OH)2D3 in M-DCs but not in P-DCs, whereas
dexamethasone was able to inhibit it in both DC subsets. Inhibition
of NF-B p65 phosphorylation in P-DCs by dexamethasone but
not by 1,25(OH)2D3 was confirmed in a time-course experiment
(Fig. 7B). In this experiment, the area under the curve for control
P-DCs was 34,913, which was reduced by 40% in dexametha-
sone-treated cells (area under the curve was 22,065), but was un-
affected following treatment of P-DCs with 1,25(OH)2D3 (area
under the curve was 36,270). Supporting these data, 1,25(OH)2D3
could reduce translocation of NF-B p65 to the nucleus in M-DCs
but not P-DCs. M-DCs and P-DCs were cultured for 18 h with or
without 1,25(OH)2D3 followed by stimulation for 45 min with LPS
or CpG, respectively, before staining with anti-NF-B p65 mAb
and propidium iodide (Fig. 7, C and D). Individual and merged
staining obtained by confocal microscopic analysis clearly show
translocation of NF-B p65 to the nucleus in stimulated M-DCs,
whereas NF-B p65 is mostly retained in the cytoplasm in cells
treated with 1,25(OH)2D3 (Fig. 7C). Conversely, the nuclear trans-
location induced in P-DCs by CpG stimulation is not affected by
1,25(OH)2D3 treatment (Fig. 7D).
Discussion
VDR agonists share with other immunomodulatory agents, and in
particular with immunosuppressive and anti-inflammatory drugs,
the capacity to target DCs, rendering them tolerogenic and foster-
ing the induction of regulatory rather than effector T cells (12, 24).
Multiple mechanisms contribute to induction of DC tolerogenicity
by VDR agonists, from down-regulation of costimulatory mole-
cules, both membrane-bound as CD40, CD80, CD86 and secreted
as IL-12, to up-regulation of anti-inflammatory molecules like
IL-10 (4, 25). Additional mechanisms involve modulation of che-
mokine secretion, enhancing the production of chemokines able to
recruit regulatory/suppressor T cells, and inhibiting chemokine
production by target organs in autoimmune diseases (26, 27).
These effects are not limited to in vitro activity: 1,25(OH)2D3 and
its analogs can also induce DCs with tolerogenic properties in
vivo, as demonstrated in models of allograft rejection (28, 29).
Tolerogenic DCs induced by a short treatment with 1,25(OH)2D3
are probably responsible for the capacity of this hormone to
induce CD4CD25 regulatory T cells that are able to mediate
transplantation tolerance (28) and arrest the development of
type 1 diabetes (30).
CCL22 and CCL17 are chemokines able to recruit activated T
cells, and in particular Th2 cells, via CCR4 (31, 32). In addition,
these chemokines can recruit CD4CD25 regulatory T cells (33).
CCL22, a chemokine mostly produced by DCs (34), has been
found to selectively recruit, in ovarian carcinoma patients,
Foxp3CCR4CD4CD25 regulatory T cells able to suppress
antitumor responses, leading to reduced patient survival (35). Sim-
ilarly, CCL22 secreted by lymphoma B cells attracts Foxp3
CCR4CD4CD25 regulatory T cells able to suppress prolifer-
ation and cytokine production by tumor-infiltrating CD4CD25
T cells (36). We have found that, in contrast to the high production
by circulating M-DCs, the CCR4 agonists CCL17 and CCL22 are
very poorly produced by unstimulated P-DCs and only CCL22 is
secreted at high levels by this DC subset following CD40 ligation,
as previously reported (17). Blood-borne M-DCs, in contrast to
P-DCs, constitutively produce high levels of CCL17 and CCL22
ex vivo, which are further enhanced by CD40 stimulation, con-
firming previous data (17). This high constitutive and inducible
production of CCR4 agonists by immature M-DCs could lead to
the preferential attraction of CD4CD25 regulatory T cells. In-
triguingly, the production of CCL22 is markedly enhanced by
1,25(OH)2D3 in blood M-DCs, indicating that VDR agonists may
favor the recruitment of regulatory T cells by this DC subset.
1,25(OH)2D3 not only regulates in M-DCs production of chemo-
kines potentially able to recruit regulatory T cells, but also en-
hances their induction, a novel finding consistent with previous in
vivo data (28, 30). Conversely, neither CCL22 nor CCL17 are
modulated by 1,25(OH)2D3 in P-DCs, and although this DC subset
induces regulatory T cells, consistent with previous reports (37,
38), this property is not modified by 1,25(OH)2D3. However, other
chemokines may be involved in regulatory T cell recruitment by
P-DCs, which produce large quantities of the CCR5 agonist CCL4
(17). Thus, in analogy with the proposed role for CCL4 in
CD4CD25 regulatory T cell attraction by activated B cells (39),
P-DCs could recruit them via secretion of this chemokine.
In addition to CCL22 and CCL17, neither IFN-, the signature
cytokine produced by P-DCs (16), nor expression of MHC class II
molecules, CD40, CD80, CD86 costimulatory molecules, or ILT3
inhibitory molecule are affected in P-DCs by 1,25(OH)2D3 treat-
ment. Conversely, production of IL-12, the M-DC signature cyto-
kine (16), as well as MHC class II and costimulatory molecule
expression are markedly inhibited by 1,25(OH)2D3 in M-DCs,
while the inhibitory molecule ILT3 is strongly up-regulated. In-
terestingly, these novel findings confirm in blood M-DCs the ca-
pacity of 1,25(OH)2D3, previously observed in monocyte-derived
DCs (6, 11), to inhibit MHC class II and costimulatory molecule
expression while up-regulating the inhibitory molecule ILT3. All
these molecules are controlled by NF-B, a signal transduction
pathway crucially involved in the inflammatory response (23). In
particular, production of IL-12 (40, 41), type I IFNs (42), CCL17
(43, 44), CCL22 (44–46), and expression of MHC class II mole-
cules (47), CD40 (48), CD80 (49), CD86 (50), and ILT3 (22) have
been shown to be regulated by NF-B activity. Our data showing
inhibition of NF-B p65 phosphorylation and nuclear translocation
by 1,25(OH)2D3 in M-DCs but not P-DCs demonstrate a mecha-
nism of action selectively targeting NF-B in DC subpopulations.
The selective targeting of NF-B components by VDR agonists in
M-DCs could thus contribute to explain the lack of activity of
these agents on cytokine and chemokine production by P-DCs,
which nevertheless respond to 1,25(OH)2D3, as shown by cyp24
up-regulation.
NF-B is a target for many anti-inflammatory and immunosup-
pressive agents (12), including glucocorticoids, anti-inflammatory
drugs that bind to a nuclear receptor in the same superfamily as the
VDR, as shown by the observation that dexamethasone up-regu-
lates the transcription of Nfkbia, resulting in increased rate of IB
synthesis and in reduced NF-B p65 phosphorylation and trans-
location to the nucleus (51, 52). Our results show that
1,25(OH)2D3 and dexamethasone exert opposite effects on CCL17
and CCL22 regulation in both M-DCs and P-DCs. Strikingly,
dexamethasone markedly enhances constitutive and inducible
CCL17 production in M-DCs, and induces it in P-DCs. Differential
effects of these anti-inflammatory agents on chemokine production
by bone marrow-derived DCs have been reported, possibly due to
differential regulation of NF-B family members by the two ste-
roid pathways (53, 54). Additional levels of NF-B regulation by
1,25(OH)2D3 and dexamethasone have also been reported in other
immune and nonimmune cell types, including up-regulation of
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IB, direct intranuclear binding of NF-B proteins, and direct
negative regulation of NF-B-induced genes (26, 40, 51, 52, 55,
56). This complex regulation could also explain the increased
CCL22 and decreased CCL17 production induced by 1,25(OH)2D3
in M-DCs.
DCs are able to synthesize 1,25(OH)2D3 in vitro as a conse-
quence of increased 1-hydroxylase expression (57), and this
could also contribute to promote regulatory T cell induction and
recruitment. It is also possible that 1,25(OH)2D3 may contribute to
the physiological control of immune responses, and possibly be
also involved in maintaining tolerance to self Ags, as suggested by
the enlarged lymph nodes containing a higher frequency of mature
DCs in VDR-deficient mice (29). Our results showing increased
induction of suppressor CD4 T cell activity by M-DCs in the
presence of 1,25(OH)2D3 support this possibility. Conversely,
1,25(OH)2D3 does not modulate the intrinsic tolerogenic capacity
of P-DCs, consistent with earlier observations showing selective
up-regulation of the inhibitory receptor ILT3 on M-DCs, without
affecting its high expression on P-DC (11). Because P-DCs are key
cells linking innate and adaptive immunity (16), the lack of up-
regulation by 1,25(OH)2D3 of their constitutive tolerogenic func-
tion may contribute to explain the intact host resistance against
infectious agents following 1,25(OH)2D3 administration (58).
In conclusion, 1,25(OH)2D3 appears to up-regulate tolerogenic
properties in M-DCs, down-regulating IL-12 and Th1 cell devel-
opment, while promoting CD4 suppressor T cell activity and
enhancing the production of CCL22, a chemokine able to recruit
regulatory T cells. In contrast, no immunomodulatory effects in-
duced by 1,25(OH)2D3 are observed in P-DCs, a DC subset prone
to favor tolerance under steady-state conditions (16) or during an
immune response (59). Indeed, P-DCs, characterized by an intrin-
sic ability to prime naive CD4 T cells to differentiate into IL-
10-producing T cells (60–63) and CD4CD25 regulatory T cells
(38), and to suppress immune responses (64, 65), may represent
naturally occurring regulatory DCs (16). The lack of immunoregu-
latory feature modulation by 1,25(OH)2D3 in P-DCs would thus
leave their tolerogenic potential unmodified.
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